2010 Immunity Vaccines 
European Pharmaceutical Review
JULY 12, 2023
The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.
European Pharmaceutical Review
AUGUST 26, 2022
Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World Pharma News
FEBRUARY 25, 2025
Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma. Since then, many therapeutic - as opposed to preventive - cancer vaccines have been in development, but none approved.
Pharmaceutical Technology
OCTOBER 28, 2022
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
pharmaphorum
OCTOBER 12, 2022
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.
pharmaphorum
DECEMBER 23, 2022
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. The post After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer appeared first on.
PharmaShots
FEBRUARY 21, 2023
Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines.
Expert insights. Personalized for you.
98 
Let's personalize your content